- Conditions
- Sickle Cell Anemia, Sickle ß0-Thalassemia
- Interventions
- L-glutamine, Placebo
- Drug
- Lead sponsor
- Emmaus Medical, Inc.
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 31
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Inglewood, California + 23 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 2,896
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Interventions
- Questionnaire Administration, Sotrovimab, Biospecimen Collection
- Other · Biological · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Dystocia
- Interventions
- Oxytocin, Sodium Chloride 0.9%
- Drug · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 1,003 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Pancreatic Cancer
- Interventions
- bevacizumab, capecitabine, gemcitabine hydrochloride
- Biological · Drug
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 2
- States / cities
- Buffalo, New York • Cleveland, Ohio
- Conditions
- Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
- Interventions
- ATV, DRV, Cobicistat, BR, F/TAF, LPV/r, Third Unboosted Drug, Cobicistat TOS, F/TAF TOS
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 4 Weeks to 17 Years
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 7
- States / cities
- Long Beach, California • Los Angeles, California • Aurora, Colorado + 4 more
- Conditions
- DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma, Mediastinal Large B-cell Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
- Interventions
- Bridging radiation therapy, Liso-cel, Post-infusion radiation
- Radiation · Biological
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Metastatic Breast Cancer
- Interventions
- Trastuzumab plus Pertuzumab, Hormonal Therapy with Anastrozole and Fulvestrant, Chemotherapy with Eribulin
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 60 Years and older · Female only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Brain Metastases, Lung Cancer, Breast Cancer, Melanoma, Malignant Glioma
- Interventions
- 2B3-101, Trastuzumab, 2B3-101 60 mg/m2 every 4 weeks, 2B3-101 50 mg/m2 every 3 weeks
- Drug
- Lead sponsor
- BBB-Therapeutics B.V.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- End Stage Renal Disease (ESRD)
- Interventions
- Tocilizumab, Intravenous Immunoglobulin
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Colorectal Cancer
- Interventions
- bevacizumab, cetuximab, capecitabine, oxaliplatin
- Biological · Drug
- Lead sponsor
- Herbert Hurwitz
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 2
- States / cities
- Durham, North Carolina • Winston-Salem, North Carolina
- Conditions
- Hookworm Infection, Hookworm Disease
- Interventions
- Na-GST-1/Alhydrogel®, CpG 10104
- Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Leukemia
- Interventions
- cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, leucovorin calcium, mercaptopurine, methotrexate, pegaspargase, thioguanine, vincristine sulfate
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 9 Years
- Enrollment
- 838 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 108
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 82 more
- Conditions
- Recurrent Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
- Interventions
- Bevacizumab, Laboratory Biomarker Analysis, Temsirolimus, Therapeutic Conventional Surgery
- Biological · Other · Drug + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Charlottesville, Virginia
- Conditions
- Histiocytosis, Langerhans-cell
- Interventions
- alemtuzumab, fludarabine phosphate, melphalan, stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Not listed
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Lymphoma, B-cell Lymphoma
- Interventions
- Leukapheresis, Stem Cell Transplant, CD19-specific T Cell Infusion, IL-2, Carmustine, Etoposide, Cytarabine, Melphalan
- Procedure · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Biliary Tract Cancer
- Interventions
- Durvalumab, Gemcitabine monotherapy, Gemcitabine + cisplatin, Gemcitabine + oxaliplatin, Gemcitabine + carboplatin, Gemcitabine + cisplatin + S-1, Gemcitabine + S-1, Gemcitabine + cisplatin + albumin-bound paclitaxel
- Biological · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 4
- States / cities
- Mobile, Alabama • Orange, California • Washington D.C., District of Columbia + 1 more
- Conditions
- Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage IV Renal Cell Cancer
- Interventions
- Bevacizumab, Sorafenib Tosylate, Pharmacological Study, Laboratory Biomarker Analysis
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Philadelphia, Pennsylvania • Nashville, Tennessee
- Conditions
- Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis
- Interventions
- CD101, Caspofungin, Fluconazole, intravenous placebo, oral placebo
- Drug
- Lead sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Davis, California • Miami, Florida + 12 more
- Conditions
- HER2/Neu Positive, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
- Interventions
- Entinostat, Laboratory Biomarker Analysis, Lapatinib Ditosylate, Trastuzumab
- Drug · Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Interventions
- trastuzumab, gefitinib, laboratory biomarker analysis
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Stage IIIA Hepatocellular Carcinoma, Stage IIIB Hepatocellular Carcinoma, Stage IIIC Hepatocellular Carcinoma, Stage IVA Hepatocellular Carcinoma, Stage IVB Hepatocellular Carcinoma
- Interventions
- Laboratory Biomarker Analysis, Nivolumab, Yttrium Y 90 Glass Microspheres
- Other · Biological · Radiation
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma
- Interventions
- Laboratory Biomarker Analysis, Pembrolizumab, Rituximab, Obinutuzumab
- Other · Biological
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- dimethyl fumarate, Interferon β-1a
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Charlottesville, Virginia
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Cisplatin & Gemcitabine, Cisplatin & Pemetrexed, Docetaxel & Gemcitabine, Pemetrexed & Gemcitabine
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 8
- States / cities
- Durham, North Carolina • Henderson, North Carolina • Laurinburg, North Carolina + 5 more